GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8(+) T cell responses leading to tumor regression

BACKGROUND: Prophylactic vaccines are available for women and girls not yet infected with HPV, but women already infected with HPV need a treatment to prevent progression to high-grade cervical lesions and cancer. GTL001 is a bivalent therapeutic vaccine for eradicating HPV-infected cells that conta...

Descripción completa

Detalles Bibliográficos
Autores principales: Esquerré, Michaël, Bouillette-Marussig, Myriam, Goubier, Anne, Momot, Marie, Gonindard, Christophe, Keller, Hélène, Navarro, Astrid, Bissery, Marie-Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354464/
https://www.ncbi.nlm.nih.gov/pubmed/28301611
http://dx.doi.org/10.1371/journal.pone.0174038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354464/
https://www.ncbi.nlm.nih.gov/pubmed/28301611
http://dx.doi.org/10.1371/journal.pone.0174038

Ejemplares similares